Perianal Fistulizing Crohn's Disease: A Call to Action

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 1, 2008, Pages 7-10

  Kamm, Michael A ^a   Ng, Siew C ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANUS FISTULA; ARTICLE; CROHN DISEASE; DISTRESS SYNDROME; EMOTIONAL STRESS; FECES INCONTINENCE; HUMAN; PAIN; PROGNOSIS; TREATMENT INDICATION; TREATMENT PLANNING;

ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; CROHN DISEASE; ENDOSONOGRAPHY; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; METRONIDAZOLE; PROCTOCOLECTOMY, RESTORATIVE; RECTAL FISTULA; SURGICAL STOMAS; WOUND HEALING;

EID: 37449010335     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.10.010     Document Type: Article

References (34)

1. Schwartz D.A., Loftus Jr. E.V., Tremaine W.J., et al. The natural history of fistulising Crohn's disease in Olmsted County, Minnesota. Gastroenterology 122 (2002) 875-880
2. Bell S.J., Williams A.B., Wiesel P., et al. Clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther 17 (2003) 1145-1151
3. Armuzzi A., Ahmad T., Ling K.L., et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 52 (2003) 1133-1139
4. Satsangi J., Silverberg M.S., Vermeire S., et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55 (2006) 749-753
5. Schwartz D.A., Wiersema M.J., Dudiak K.M., et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and examination under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology 121 (2001) 1064-1072
6. Lunniss P.J., Kamm M.A., and Phillips R.K. Factors affecting continence after surgery for anal fistula. Br J Surg 81 (1994) 1382-1385
7. Yamamoto T., Allan R.N., and Keighley M.R. Effect of fecal diversion alone on perianal Crohn's disease. World J Surg 24 (2000) 1258-1262
8. Guillem J.G., Roberts P.L., Murray J.J., et al. Factors predictive of persistent or recurrent Crohn's disease in excluded rectal segments. Dis Colon Rectum 35 (1992) 768-772
9. Bernstein L.H., Frank M.S., Brandt L.J., et al. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 79 (1980) 599
10. Lichtenstein G.R. Treatment of fistulising Crohn's disease. Gastroenterology 119 (2000) 1132-1147
11. Pearson D.C., May G.R., Fick G.H., et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123 (1995) 132-142
12. Hanauer S.B., and Smith M.B. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporine. Am J Gastroenterol 88 (1993) 646-649
13. Sandborn W.J., Present D.H., Isaacs K.L., et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 125 (2003) 380-388
14. Ng S.C., Arebi N., and Kamm M.A. Medium term results of oral tacrolimus for treatment of refractory inflammatory bowel disease. Inflamm Bowel Dis 13 (2007) 129-134
15. Gonzalez-Lama Y., Abreu L., Vera M.I., et al. Long term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease. Inflamm Bowel Dis 11 (2005) 8-15
16. Hart A.L., Plamondon S., and Kamm M.A. Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. Inflamm Bowel Dis 13 (2007) 245-253
17. Loungnarath R., Dietz D.W., Mutch M.G., et al. Fibrin glue treatment of complex anal fistulas has low success rate. Dis Colon Rectum 47 (2004) 432-436
18. Vitton V., Gasmi M., Baqrthet M., et al. Long-term healing of Crohn's anal fistulas with fibrin glue injection. Aliment Pharmacol Ther 21 (2005) 1453-1457
19. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
20. Sands B.E., Anderson F.H., Bernstein C.N., et al. Randomised controlled trial of infliximab maintenance therapy for fistulizing Crohn's disease (Accent II). N Engl J Med 350 (2004) 876-885
21. Lichtenstein G.R., Yan S., Bala M., et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulising Crohn's disease. Gastroenterology 128 (2005) 862-869
22. Bell S.J., Halligan S., Windsor A.C.J., et al. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 17 (2003) 387-393
23. Van Assche G., Vanbeckevoort D., Bielen D., et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 98 (2003) 332-339
24. Shih C.E., Bayless T.M., and Harris M.C. Maintenance of long term response to infliximab over 1 to 5 years in Crohn's disease including shortening dosing intervals or increasing dosage. Gastroenterology 126 Suppl 2 (2004) W1414
25. Poritz L.S., Rowe W.A., and Koltun W.A. Remicade® does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum 45 (2002) 771-775
26. Poggioli G., Laureti S., Pierangeli F., et al. Local injection of infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum 48 (2005) 768-774
27. Asteria C.R., Fiacari F., Bagnoli S., et al. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-α accounts for a favourable clinical response in selected cases: a pilot study. Scand J Gastroenterol 41 (2006) 1064-1072
28. Vasiliauskas E.A., Kam L.Y., Abreu-Martin M.T., et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid dependent Crohn's disease. Gastroenterology 117 (1999) 1278-1287
29. Ehrenpreis E.D., Kane S.V., Cohen L.B., et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117 (1999) 1271-1277
30. Plamondon S., Ng S.C., and Kamm M.A. Thalidomide in luminal and fistulising Crohn's disease resistant to standard therapy. Aliment Pharmacol Ther 25 (2007) 557-567
31. Sandborn W.J., Hanauer S., Loftus Jr. E.V., et al. An open-label study of human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99 (2004) 1984-1989
32. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM Trial. Gastroenterology 132 (2007) 52-65
33. Kamm M.A., Colombel J.F., Sandborn W.J., et al. Adalimumab maintains clinical remission and response, induces and maintains healing of draining fistulas in patients with active Crohn's disease (abstr). Gut 56 Suppl II (2007) A21
34. Connell W.R., Sheffield J.P., Kamm M.A., et al. Lower gastrointestinal malignancy in Crohn's disease. Gut 35 (1994) 347-352